References in periodicals archive ?
TRE-515 is a novel, first-in-class inhibitor of deoxycytidine kinase for the treatment of patients with myelodysplastic syndromes (MDS).
While hypomethylating agents are a mainstay of treatment for myelodysplastic syndromes, these agents alone produce remissions in a minority of patients and are not curative," said Meagan A.
The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
In 6 patients having myelodysplastic syndrome 3 patients were diagnosed with refractory anaemia with excess blasts type-1, 2 patients with refractory cytopenia with multi lineage dysplasia and 1 patient with childhood myelodysplasia.
This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Nenet was diagnosed with myelodysplastic syndrome last October.
Myelodysplastic syndrome (MDS) is a heterogenous group of hematopoietic stem cell disorders that are multifactorial in their etiology and often difficult to distinguish from hematological benign diseases with unilineage or multilineage cytopenia such as aplastic anemia (AA) both in clinic and laboratory.
The majority of patients with myelodysplastic syndrome (MDS) have hypercellular bone marrow (BM) (cellularity level greater than 60%).
Fighting back tears on several occassions, Robin Roberts said her myelodysplastic syndrome was caused by her treatment for breast cancer, which she beat five years ago.
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
The National Institute for Health and Clinical Excellence (Nice) said it has ruled in draft guidance that azacitidine could not be prescribed on the NHS for the treatment of a number of myelodysplastic syndromes (MDS).
The study showed that patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome - a pre-leukemic condition - experienced a remission with the help of combination of low-intensity chemotherapy, targeted radiation delivery by an antibody and a stem-cell transplant.